HM 100714
Alternative Names: HM-100714Latest Information Update: 10 Mar 2025
At a glance
- Originator Hanmi Pharmaceutical
- Class Antineoplastics; Small molecules
- Mechanism of Action ERBB 2 receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 04 Aug 2026 Hanmi Pharmaceutical announces intention to submit an IND application for Solid tumours (Hanmi Pharmaceutical Pipeline, August 2026)
- 22 Apr 2026 Pharmacodynamics, pharmacokinetics and adverse events data from a preclinical study in Solid tumours presented at the 117th Annual Meeting of the American Association for Cancer Research (AACR-2026)
- 25 Apr 2025 Pharmacodynamics data from preclinical in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)